Company Information

ProMIS™ Neurosciences, Inc. (Nasdaq: PMN), is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company has offices in Toronto, Ontario, and Cambridge, Massachusetts.